Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Contemporary analysis of functional immune recovery to opportunistic and vaccine-preventable infections after allogeneic haemopoietic stem cell transplantation.

de Silva HD, Ffrench RA, Korem M, Orlowski E, Curtis DJ, Spencer A, Avery S, Patil S, Morrissey CO.

Clin Transl Immunology. 2018 Oct 5;7(10):e1040. doi: 10.1002/cti2.1040. eCollection 2018.

2.

Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.

Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.

J Gastroenterol Hepatol. 2013 Nov;28(11):1770-81. doi: 10.1111/jgh.12265.

3.

Impaired hepatitis C virus (HCV)-specific interferon-γ responses in individuals with HIV who acquire HCV infection: correlation with CD4(+) T-cell counts.

Flynn JK, Dore GJ, Matthews G, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.

J Infect Dis. 2012 Nov 15;206(10):1568-76. doi: 10.1093/infdis/jis544. Epub 2012 Sep 4.

4.

Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group.

J Viral Hepat. 2011 Aug;18(8):549-61. doi: 10.1111/j.1365-2893.2010.01335.x. Epub 2010 Jul 5.

5.

The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo.

Tye-Din JA, Anderson RP, Ffrench RA, Brown GJ, Hodsman P, Siegel M, Botwick W, Shreeniwas R.

Clin Immunol. 2010 Mar;134(3):289-95. doi: 10.1016/j.clim.2009.11.001. Epub 2009 Nov 25.

PMID:
19942485
6.

Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors.

Jones KL, Brown LE, Eriksson EM, Ffrench RA, Latour PA, Loveland BE, Wall DM, Roberts SK, Jackson DC, Gowans EJ.

J Viral Hepat. 2008 Oct;15(10):761-72. doi: 10.1111/j.1365-2893.2008.01003.x. Epub 2008 Jul 10.

PMID:
18637077
7.

Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection.

Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, Ffrench RA.

Immunol Cell Biol. 2007 Jan;85(1):24-32. Epub 2006 Nov 28. Review.

PMID:
17130897
8.

Protective immunity against hepatitis C virus infection.

Elliot LN, Lloyd AR, Ziegler JB, Ffrench RA.

Immunol Cell Biol. 2006 Jun;84(3):239-49. Review.

PMID:
16509830
9.

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Gao K, Medveckzy J, Ffrench RA, Ramshaw IA.

Vaccine. 2005 Sep 7;23(38):4647-57.

PMID:
15964105
11.

Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use.

Freeman AJ, Ffrench RA, Post JJ, Harvey CE, Gilmour SJ, White PA, Marinos G, van Beek I, Rawlinson WD, Lloyd AR.

J Infect Dis. 2004 Sep 15;190(6):1093-7. Epub 2004 Aug 10.

PMID:
15319859
12.

Polymorphism report: identification of two common single nucleotide polymorphisms in the human toll-like receptor 5 (TLR5) gene.

Kao YL, Ffrench RA, Williams G.

Mol Cell Probes. 2004 Jun;18(3):205. No abstract available.

PMID:
15135456
13.

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.

Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, Haber PS, Marinos G, Levy MH, Kaldor JM, Dolan KA, Ffrench RA, Lloyd AR, Rawlinson WD; Hepatitis C Incidence and Transmission in Prisons Study (HITS) Group.

J Infect Dis. 2004 May 15;189(10):1846-55. Epub 2004 Apr 26.

PMID:
15122521
14.

Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.

Keoshkerian E, Ashton LJ, Smith DG, Ziegler JB, Kaldor JM, Cooper DA, Stewart GJ, Ffrench RA.

J Med Virol. 2003 Dec;71(4):483-91.

PMID:
14556259
15.

Altered lymphocyte heat shock protein 70 expression in patients with HIV disease.

Agnew LL, Kelly M, Howard J, Jeganathan S, Batterham M, Ffrench RA, Gold J, Watson K.

AIDS. 2003 Sep 5;17(13):1985-8.

PMID:
12960833
16.

Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation.

Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, Marinos G, Lloyd AR.

J Leukoc Biol. 2003 Sep;74(3):360-9.

PMID:
12949239
17.

Transmembrane T-cell receptor peptides inhibit B- and natural killer-cell function.

Huynh NT, Ffrench RA, Boadle RA, Manolios N.

Immunology. 2003 Apr;108(4):458-64.

18.

The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection.

Freeman AJ, Pan Y, Harvey CE, Post JJ, Law MG, White PA, Rawlinson WD, Lloyd AR, Marinos G, Ffrench RA.

J Hepatol. 2003 Mar;38(3):349-56.

PMID:
12586302
19.

Quantification of hepatitis C virus in human liver and serum samples by using LightCycler reverse transcriptase PCR.

White PA, Pan Y, Freeman AJ, Marinos G, Ffrench RA, Lloyd AR, Rawlinson WD.

J Clin Microbiol. 2002 Nov;40(11):4346-8.

20.

Immunity against hepatitis C virus infection.

Post JJ, Freeman AJ, Harvey CE, Ffrench RA, Lloyd AR.

Lancet. 2002 Sep 28;360(9338):1020; author reply 1020-1. No abstract available.

PMID:
12383686
21.

Immunopathogenesis of hepatitis C virus infection.

Freeman AJ, Marinos G, Ffrench RA, Lloyd AR.

Immunol Cell Biol. 2001 Dec;79(6):515-36. Review.

PMID:
11903612
22.
23.

In vitro HIV-specific CTL activity from HIV-seropositive individuals is augmented by interleukin-12 (IL-12).

Young JM, Ffrench RA, Clarkson JD, Stewart GJ, Liang T, Tideman RL, Packham D, Fulcher DA, Benson EM.

AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):233-42.

PMID:
11177406
24.

Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.

Woodberry T, Gardner J, Mateo L, Eisen D, Medveczky J, Ramshaw IA, Thomson SA, Ffrench RA, Elliott SL, Firat H, Lemonnier FA, Suhrbier A.

J Virol. 1999 Jul;73(7):5320-5.

25.

A preliminary study to determine the effect of an infusion of cryopreserved autologous lymphocytes on immunocompetence and viral load in HIV-infected patients.

Trickett AE, Kelly M, Cameron BA, Lloyd A, Ffrench RA, Dwyer JM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):129-36.

PMID:
9473013
26.

Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.

Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM.

AIDS. 1997 Dec;11(15):1833-8.

PMID:
9412701
27.

Is recovery from HIV infection possible?

Ziegler JB, Ffrench RA.

Med J Aust. 1995 Aug 21;163(4):173. No abstract available.

PMID:
7651246
28.

Class II-restricted T-cell clones to a synthetic peptide of influenza virus hemagglutinin differ in their fine specificities and in the ability to respond to virus.

Ffrench RA, Tang XL, Anders EM, Jackson DC, White DO, Drummer H, Wade JD, Tregear GW, Brown LE.

J Virol. 1989 Jul;63(7):3087-94.

29.

Distinct epitopes recognized by I-Ad-restricted T-cell clones within antigenic site E on influenza virus hemagglutinin.

Brown LE, Ffrench RA, Gawler JM, Jackson DC, Dyall-Smith ML, Anders EM, Tregear GW, Duncan L, Underwood PA, White DO.

J Virol. 1988 Jan;62(1):305-12.

30.

Characterization of subtype-specific and cross-reactive helper-T-cell clones recognizing influenza virus hemagglutinin.

Brown LE, Katz JM, Ffrench RA, Anders EM, White DO.

Cell Immunol. 1987 Oct 1;109(1):12-24.

PMID:
2958139
31.

Supplemental Content

Loading ...
Support Center